Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) CEO Dennis Hancock and Director of Life Sciences Mike Farber joined Steve Darling from Proactive to bring news the company has filed a cancer patent for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens.
Farber explains what this means and why protecting this intellectual property is so important.
Hancock telling Proactive the company has also announced they will be proceeding with three separate pre-clinical trials with specialized third-party cancer CROs. Farber say they are looking at Ivermectin triple-negative breast cancer; metastatic melanoma, and Lewis Lung Carcinoma